It's important to note that GLP-1 receptor agonists like Wegovy are associated with an increased risk of gallbladder problems, including gallstones and inflammation of the gallbladder (cholecystitis)
This study published in the Annals of the Rheumatic Diseases indicates that GLP-1 receptor agonists might be disease-modifying for knee OA patients with comorbid T2DM, possibly mediated by weight loss, Lane said
Treatment discussion If appropriate, semaglutide options such as Ozempic, Wegovy, or compounded semaglutide may be discussed with structured guidance
oncology bispecifics and ADCs pipeline Therapeutic Segments: Oncology (Tagrisso, Imfinzi, Lynparza, Calquence)
Realistic expectations account for evidence limitations
Generally, one gram per kilogram (2.2 pounds) of body weight is recommended